Literature DB >> 29166246

Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.

Seo-Youn Choi1, Seong Hyun Kim1, Cheol Keun Park1, Ji Hye Min1, Ji Eun Lee1, Yoon-Hyeong Choi1, Bo Ra Lee1.   

Abstract

Purpose To determine the preoperative magnetic resonance (MR) imaging findings potentially most useful for predicting cytokeratin 19 (CK19)-positive hepatocellular carcinoma (HCC) and to evaluate the prognosis after curative resection in patients with a single HCC lesion positive for CK19 compared with patients with HCC who are negative for CK19. Materials and Methods The institutional review board approved this study and waived the requirement for informed consent. Two hundred four patients with CK19-negative HCC and 38 with CK19-positive HCC who underwent curative resection after gadoxetic acid-enhanced and diffusion-weighted MR imaging were retrospectively evaluated in a single institution. Two radiologists evaluated preoperative findings at MR imaging. Significant findings for differentiating the two groups were identified at univariate and multivariate analyses. By using receiver operating characteristic analysis, the optimal cut-off values for quantitative variables were determined. Recurrence-free survival rates after surgery were also compared between groups. Results At multivariate analysis, irregular tumor margin (P = .024), arterial rim enhancement (P < .001), lower tumor-to-liver signal intensity (SI) ratio on hepatobiliary phase (HBP) images (≤0.522; P = .01), and lower tumor-to-liver apparent diffusion coefficient (ADC) ratio (≤0.820; P < .001) were independent significant factors to predict CK19-positive HCC. When three of these four criteria were combined, 63.2% (24 of 38; 95% confidence interval: 46.0%, 78.2%) of CK19-positive HCCs were identified with a specificity of 90.7% (185 of 204; 95% confidence interval: 46.0%, 78.2%). When all four criteria were satisfied, specificity was 99.5% (203 of 204; 95% confidence interval: 97.3%, 100%). Recurrence-free survival rates were significantly lower in patients with CK19-positive HCCs compared with those with CK19-negative HCCs after curative resection (63.9% vs 90.0% at 1 year, 63.9% vs 79.9% at 2 years, and 54.8% vs 70.2% at 3 years, P = .001 by log-rank test). Conclusion At gadoxetic acid-enhanced and diffusion-weighted MR imaging, irregular margin, arterial phase rim enhancement, lower tumor-to-liver ADC ratio, and lower tumor-to-liver SI ratio at HBP imaging may be helpful to predict CK19-positive HCC with early recurrence (<2 years) after curative resection. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29166246     DOI: 10.1148/radiol.2017162846

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

Review 1.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

2.  The prognostic value of homeobox B7 expression in patients with hepatocellular carcinoma.

Authors:  Yarong Guo; Xiaojiang Qin; Bao Chai; Junmei Jia; Jiahong Yi; Kang Wang; Xiaomin Hou
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

Review 3.  Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression.

Authors:  Hyungjin Rhee; Haeryoung Kim; Young Nyun Park
Journal:  Liver Cancer       Date:  2020-10-23       Impact factor: 11.740

Review 4.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

5.  MRI features associated with HCC histologic subtypes: a western American and European bicenter study.

Authors:  Sébastien Mulé; Ali Serhal; Athena Galletto Pregliasco; Jessica Nguyen; Camila Lopes Vendrami; Edouard Reizine; Guang-Yu Yang; Julien Calderaro; Giuliana Amaddeo; Alain Luciani; Frank H Miller
Journal:  Eur Radiol       Date:  2022-08-24       Impact factor: 7.034

6.  Noninvasive prediction of HCC with progenitor phenotype based on gadoxetic acid-enhanced MRI.

Authors:  Jie Chen; Zhenru Wu; Chunchao Xia; Hanyu Jiang; Xijiao Liu; Ting Duan; Likun Cao; Zheng Ye; Zhen Zhang; Ling Ma; Bin Song; Yujun Shi
Journal:  Eur Radiol       Date:  2019-09-16       Impact factor: 5.315

7.  Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Authors:  Lin Sun; Luwen Mu; Jing Zhou; Wenjie Tang; Linqi Zhang; Sidong Xie; Jingbiao Chen; Jin Wang
Journal:  Cancer Immunol Immunother       Date:  2021-05-16       Impact factor: 6.968

8.  Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.

Authors:  Yanfen Fan; Yixing Yu; Mengjie Hu; Ximing Wang; Mingzhan Du; Lingchuan Guo; Chunhong Hu
Journal:  Br J Radiol       Date:  2021-01-20       Impact factor: 3.039

Review 9.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

Review 10.  HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.

Authors:  Sandeep Arora; Roberta Catania; Amir Borhani; Natally Horvat; Kathryn Fowler; Carla Harmath
Journal:  Abdom Radiol (NY)       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.